Pasithea Therapeutics Corp(KTTA)
$0.52+0.00 (+0.58%)
KTTA
Pasithea Therapeutics Corp financials statements
$0.52
At close:+0.00 (+0.58%)
Pasithea Therapeutics Corp (KTTA) Ratios
153 Followers
Pasithea Therapeutics Corp Ratios
KTTA's free cash flow for Q3 2026 was $-13.97B. For the 2026 fiscal year, KTTA's free cash flow was increased by $4.00 and operating cash flow was $-13.97B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 11.35 | 6.58 | 6.34 | 18.15 | 119.17 |
| Quick Ratio | 11.35 | 6.58 | 6.34 | 18.15 | 119.17 |
| Cash Ratio | 11.09 | 6.18 | 6.20 | 17.62 | 118.42 |
| Solvency Ratio | -3.94 | -10.34 | -5.63 | -5.19 | -1.14 |
| Operating Cash Flow Ratio | -3.06 | -12.43 | -5.10 | -7.29 | -7.10 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 51.44M | $ 6.09M | $ 13.97M | $ 31.39M | $ 51.40M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.09 | 1.09 | 1.12 | 1.06 | 1.04 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -114929.32 | -8870.15 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -123421.28 | -8872.86 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.06 | 0.40 | 0.00 |
| Net Debt to EBITDA | 2.73 | 0.51 | 1.06 | 2.78 | 11.75 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -14.69% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | -29925.73% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | -29916.57% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -29925.73% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -14430.49% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -14430.49% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -14430.49% |
| Net Income Per EBT | 100.00% | 100.00% | 102.93% | 118.83% | 100.00% |
| EBT Per EBIT | 97.94% | 97.58% | 97.05% | 93.16% | 48.22% |
| Return on Assets (ROA) | -33.91% | -86.55% | -61.12% | -30.85% | -4.08% |
| Return on Equity (ROE) | -36.99% | -94.06% | -68.22% | -32.79% | -4.23% |
| Return on Capital Employed (ROCE) | -37.74% | -95.35% | -68.05% | -29.07% | -8.52% |
| Return on Invested Capital (ROIC) | -37.74% | -95.35% | -67.81% | -28.96% | -8.52% |
| Return on Tangible Assets | -36.18% | -185.63% | -94.38% | -39.43% | -4.08% |
| Earnings Yield | -225.22% | -402.72% | -170.92% | -85.98% | -5.34% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.75 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -106146.14 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 106146.14 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.16 | -12.70 | -10.64 | -10.85 | -2.76 |
| Free Cash Flow Per Share | -2.16 | -12.70 | -10.67 | -10.93 | -2.78 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -6961719.00 | -391.40 | -127.83 | -147.61 |
| Capital Expenditure Coverage Ratio | 0.00 | -6961719.00 | -391.40 | -127.83 | -147.61 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | -164.37 | -27.14 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -210.73 |
| Free Cash Flow Yield | -167.71% | -403.27% | -144.13% | -85.13% | -7.85% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.44 | -0.25 | -0.59 | -1.16 | -18.74 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 2703.81 |
| Price-to-Book (P/B) Ratio | 0.16 | 0.23 | 0.40 | 0.38 | 0.79 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.60 | -0.25 | -0.69 | -1.17 | -12.74 |
| Price-to-Operating Cash Flow Ratio | -0.60 | -0.25 | -0.70 | -1.18 | -12.83 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | -0.79 | -0.03 | -0.00 | -0.01 |
| Enterprise Value Multiple | 2.28 | 0.26 | 0.45 | 1.40 | 2.72 |
| Enterprise Value | -46.09M | -3.47M | -6.91M | -16.38M | -12.24M |
| EV to EBITDA | 2.28 | 0.26 | 0.45 | 1.40 | 2.72 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | -812.77 |
| EV to Free Cash Flow | 3.03 | 0.25 | 0.51 | 1.19 | 3.83 |
| EV to Operating Cash Flow | 3.03 | 0.25 | 0.51 | 1.20 | 3.86 |
| Tangible Book Value Per Share | 7.32 | 5.66 | 11.25 | 25.88 | 44.70 |
| Shareholders’ Equity Per Share | 7.85 | 13.49 | 18.54 | 33.67 | 44.70 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Net Income Per Share | -2.91 | -12.69 | -12.65 | -11.04 | -1.89 |
| Tax Burden | 1.00 | 1.00 | 1.03 | 1.19 | 1.00 |
| Interest Burden | 0.98 | 0.98 | 0.97 | 1.00 | 0.48 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 31.29 |
| Income Quality | 0.74 | 1.00 | 0.87 | 1.17 | 1.46 |
Currency in USD
